---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027752"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2026-06-08T21:00:43+00:00"
generated_at: "2026-06-08T21:02:45.071848+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CFO Alan Weichselbaum departs; Andriy Mushak appointed fractional CFO at $6K/month

## Summary
- Alan Weichselbaum departs as CFO effective June 6, 2026; no disagreement cited.
- Andriy Mushak, CPA, appointed fractional CFO effective June 6, 2026; will serve as independent contractor.
- Mushak will receive $6,000 per month under a one-year consulting agreement with LMAM Consulting Group.
- Mushak has 20+ years accounting experience; previously at Baker Tilly US, LLP and co-founded LMAM in 2025.

## SEC filing metadata
- accession: 0001493152-26-027752
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2026-06-08T21:00:43+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315226027752/0001493152-26-027752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315226027752/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027752
- JSON: https://secwatch.observer/filing/0001493152-26-027752.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027752.txt

## Key facts
- Executive change
  Andriy Mushak was appointed as fractional Chief Financial Officer at Telomir Pharmaceuticals, Inc..
  - Action: appointed
  - Role: fractional Chief Financial Officer
  source text: On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971532/000149315226027752/0001493152-26-027752-index.htm
- Executive change
  Alan Weichselbaum departed as Chief Financial Officer at Telomir Pharmaceuticals, Inc..
  - Action: will be no longer serving
  - Role: Chief Financial Officer
  source text: Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the "Company"). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971532/000149315226027752/0001493152-26-027752-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.